The HLA class I-CML association revisited taking into account the two forms of gene fusion in the Philadelphia chromosome. A multicenter study.
CML patients possess either a b3-a2 or a b2-a2 fusion between the BCR and ABL genes. Depending on the type of fusion, two different series of non-self potentially immunogenic peptides may be produced. If they are presented by HLA class I molecules and recognized by cytotoxic CD8 lymphocytes, individuals could be more susceptible or resistant to leukemic cells bearing one or the other form of fusion according to their HLA class I phenotype. To test this point, the frequencies of HLA-A and HLA-B alleles were compared between b3-a2 and the b2-a2 CML patients. In essence, no difference was found whose significance could withstand correction for multiple comparisons.
Richiardi
P M
PM
Dipartimento di Scienze Mediche, Università di Torino, Novara, Italy.
Tosi
R
R
Martinelli
G
G
Saglio
G
G
Conte
R
R
Barbanti
M
M
Dall'Omo
A
A
Farabegoli
P
P
Favoino
B
B
Gambelunghe
C
C
D001483:Base Sequence; D016009:Chi-Square Distribution; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006680:HLA Antigens / Q000032:analysis*; D015234:HLA-A Antigens / Q000032:analysis; D015235:HLA-B Antigens / Q000032:analysis; D006801:Humans; D007558:Italy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000276:immunology; D008969:Molecular Sequence Data; D010677:Philadelphia Chromosome; D016133:Polymerase Chain Reaction
D006680:HLA Antigens; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D016044:Fusion Proteins, bcr-abl